Announcement on Expected Increase in Performance for 2025
Filed with SSE · · 2 pages · Chinese
Zhejiang Starry Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Starry Pharmaceutical
- Announcement on Subsidiary Completing Industrial and Commercial Change Registration and Obtaining Business License
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Cancellation of Special Accounts for Raised Funds
- Announcement on Closing Investment Projects Financed by Raised Funds, Adjusting Investment Scale, and Using Residual Raised Funds to Permanently Supplement Current Capital
- Announcement on Returning All Raised Funds Temporarily Used for Supplementing Current Capital to Special Account for Raised Funds
Later from Zhejiang Starry Pharmaceutical
- Announcement on Release of Pledge and New Pledge of Controlling Shareholder's Shares
- Announcement on Acquisition of Equity in Ruishi Pharmaceutical
- Announcement on Outward Investment and Related Party Transactions
- Announcement on Progress in Selling Equity of Joint-stock Company
- Indicative Announcement on Election of Board of Directors at Expiry of Term of Office
Follow Zhejiang Starry Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Starry Pharmaceutical